The U.S. Food and Drug Administration (FDA) has issued a final guidance for industry titled Postapproval Pregnancy Safety Studies, focusing on methodologies to better study the safety of drugs and biological products when used during pregnancy after approval. This guidance addresses the frequent lack of sufficient human data on the effects of many medications on pregnant patients at the time of their approval.
Pregnant women often require treatment for ongoing or new health conditions, yet clinical trials typically do not provide enough information on pregnancy safety. The FDA’s guidance recommends a range of study designs, including pregnancy registries, real-world data studies, and descriptive analyses based on individual case reports, to collect more comprehensive and reliable safety information in the postmarket setting.
FDA Commissioner Marty Makary, M.D., M.P.H., highlighted the importance of this information for clinical decision-making, stating that pregnant women and their healthcare providers need clear, reliable data to make informed treatment choices. Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the Center for Drug Evaluation and Research, noted that many medical products currently used during pregnancy are done so despite inadequate clinical trial data on pregnancy safety. This guidance is intended to help identify pregnancy-related risks more promptly and improve the information available to clinicians and the public.
The guidance emphasizes incorporating expert input from fields such as obstetrics, pediatrics, genetics, and statistics in the design and interpretation of these studies. It also advises that these approaches be combined with established scientific standards—particularly best practices for observational research—and existing FDA guidances on study design, real-world evidence, pharmacovigilance, and postmarket requirements.
The FDA’s guidance documents represent the agency’s current thinking and do not impose legally enforceable requirements. The full final guidance is publicly available on the FDA website.
Why it matters
Many pregnant patients must use medications despite limited safety data, posing potential risks to both the patient and developing fetus. This guidance aims to improve postapproval data collection, enabling earlier identification of risks and more informed treatment decisions during pregnancy. Enhanced safety data also facilitates updated drug labeling that better informs healthcare providers and patients.
Background
Historically, pregnant women have been underrepresented in clinical trials due to ethical and safety concerns, resulting in a lack of robust data at drug approval. Postapproval pregnancy safety studies are critical for addressing this gap by monitoring real-world use and outcomes. The FDA’s guidance codifies approaches to enhance these studies and support ongoing evaluation of drug safety in pregnancy.
Sources
This article is based on reporting and publicly available information from the following source:
Read more Health & Public Health stories on Goka World News.